• FibroBiologics entered a securities purchase agreement with Peak One Opportunity Fund for a USD 1.2 million convertible debenture.
• Deal closed Oct. 8, 2026; Peak One paid USD 1.02 million, reflecting a 15% original issue discount.
• Debenture matures Oct. 8, 2027; carries 0% interest; converts only after default at USD 0.78 per share.
• Payment schedule requires USD 1.08 million on April 8, 2027, then USD 60,000 on July 8, 2027.
• Company issued 125,000 restricted commitment shares; conversion issuance capped at 1,671,094 shares without stockholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418065), on October 08, 2026, and is solely responsible for the information contained therein.